Michael Grundman joins NeuroPhage team on back of $21.4m series B
This article was originally published in Scrip
Privately-held biotech NeuroPhage, which is focused on a novel approach for disaggregating misfolded proteins for the treatment and prevention of neurodegenerative diseases, has appointed Dr Michael Grundman to lead the clinical development of NPT002, one of the company's two preclinical treatments for Alzheimer's disease. Dr Grundman is an Alzheimer's disease expert, and currently serves as president and CEO of Global R&D Partners, as well as adjunct professor of neurosciences at the University of California, San Diego.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.